Regulatory T cells modulate inflammation and reduce infarct volume in experimental brain ischaemia
Por favor, use este identificador para citas ou ligazóns a este ítem:
http://hdl.handle.net/10347/21865
Ficheiros no ítem
Metadatos do ítem
Título: | Regulatory T cells modulate inflammation and reduce infarct volume in experimental brain ischaemia |
Autor/a: | Brea López, David Agulla Freire, Jesús Rodríguez Yáñez, Manuel Barral, David Ramos Cabrer, Pedro Campos Pérez, Francisco Almeida, Ángeles Dávalos, Antoni Castillo Sánchez, José Antonio |
Centro/Departamento: | Universidade de Santiago de Compostela. Departamento de Psiquiatría, Radioloxía, Saúde Pública, Enfermaría e Medicina |
Palabras chave: | Cerebrovascular disease/stroke | Regulatory T cells | Inflammation | Immunomodulation | |
Data: | 2014 |
Editor: | Wiley |
Cita bibliográfica: | Brea, D., Agulla, J., Rodríguez‐Yáñez, M., Barral, D., Ramos‐Cabrer, P., Campos, F., Almeida, A., Dávalos, A. and Castillo, J. (2014), Regulatory T cells modulate inflammation and reduce infarct volume in experimental brain ischaemia. J. Cell. Mol. Med., 18: 1571-1579. doi:10.1111/jcmm.12304 |
Resumo: | Brain ischaemia (stroke) triggers an intense inflammatory response predominately mediated by the accumulation of inflammatory cells and mediators in the ischaemic brain. In this context, regulatory T (Treg) cells, a subpopulation of CD4+ T cells with immunosuppressive and anti‐inflammatory properties, are activated in the late stages of the disease. To date, the potential therapeutic usefulness of Treg cells has not been tested. In this study, we aimed to investigate whether Treg cells exert protection/repair following stroke. Both the adoptive transfer of Treg cells into ischaemic rats and the stimulation of endogenous T‐cell proliferation using a CD28 superagonist reduced the infarct size at 3–28 days following the ischaemic insult. Moreover, T cell‐treated animals had higher levels of FoxP3 and lower levels of IL‐1β, CD11b+ and CD68+ cells in the infarcted hemisphere when compared with control animals. However, T‐cell treatment did not alter the rate of proliferation of NeuN‐, NCAM‐ or CD31‐positive cells, thereby ruling out neurogenesis and angiogenesis in protection. These results suggest that adoptive transfer of T cells is a promising therapeutic strategy against the neurological consequences of stroke. |
Versión do editor: | https://doi.org/10.1111/jcmm.12304 |
URI: | http://hdl.handle.net/10347/21865 |
DOI: | 10.1111/jcmm.12304 |
E-ISSN: | 1582-4934 |
Dereitos: | © 2014 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited |
Coleccións
-
- PRSP-Artigos [373]
A licenza do ítem descríbese como
© 2014 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited
© 2014 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited